Novo Nordisk
Novo Nordisk A/S is a Danish multinational pharmaceutical company. It has factories in in nine countries. More than 48,000 people work for the company. It was started in 1989 by merging two older companies, Nordisk Insulinlaboratorium and Novo Industri.[1] It is one of Europe’s most valuable companies and a big player in the Danish economy. In September 2023 it was worth $421 billion. It plans to buy Inversago Pharma. The Wegovy weight-loss drug has been very successful.[2]
It specialises in diabetes care medications and devices. It also does hemostasis management, growth hormone therapy and hormone replacement therapy.[3]
Novo Nordisk Media
Headquarters of Novo Nordisk USA, located in Plainsboro Township, New Jersey
Danska läkemedelsjätten Novo Nordisk har sin största fabrik lokaliserad till Kalundborg (bilden) där bolaget har cirka 3.000 anställda. I mars 2013 meddelade Novo Nordisk att de investerar ytterligare 380 mio.
Charlie Kimball at the 2015 Indianapolis 500
.jpg)
References
- ↑ "Our History". web.archive.org. 2019-07-08. Archived from the original on 2019-07-08. Retrieved 2023-03-08.
- ↑ Kuchler, Hannah (2023-09-01). "Novo Nordisk briefly eclipses LVMH as Europe’s most valuable company". Financial Times. https://www.ft.com/content/97e89e94-38cb-4a22-9a17-c110e39958bc?. Retrieved 2023-09-02.
- ↑ "Novo Nordisk sees slower 2020 growth with US insulin prices pressured". CNBC. Retrieved 2023-03-08.